Navigation Links
Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
Date:9/22/2008

experienced significant improvements in clinical endpoints compared to placebo, including reductions in all cause mortality, all cause mortality or transplant, cardiovascular mortality, heart failure hospitalization, and cardiovascular hospitalization. While the most robust clinical effects occurred in the very favorable genotype group, patients with the favorable genotype also benefitted from treatment with bucindolol. Bucindolol also demonstrated clinically significant improvements in ischemic endpoints including reducing the risk of myocardial infarction.

"Bucindolol offers physicians a tremendous advantage to predict response," said William Abraham, M.D., Director of Cardiovascular Medicine at the Ohio State University Medical Center. "This is vitally important since the annual mortality rate for heart failure patients can be as high as 20 percent. With these patients, we have no time to spare."

Michael Bristow, M.D., Chairman and Chief Science and Medical Officer of ARCA biopharma, said, "While currently available beta blockers are a mainstay in medicine, it is difficult for physicians to predict which patients will respond to which therapy. Bucindolol interacts with certain polymorphisms of adrenergic receptors that help regulate cardiac function, allowing us to predict patient clinical response using a simple genetic test. The time is coming when we can realize the benefits of personalized medicine in cardiovascular disease."

About Beta Blockers

The use of beta blockers is the standard of care in patients with heart failure and left ventricular dysfunction, according to clinical practice guidelines of the Heart Failure Society of America (HFSA), the American Heart Association and the American College of Cardiology. HFSA guidelines state: "Beta-blocker therapy remains a major advance in the treatment of patients with LV systolic dysfunction. Along with ACE inhibitors, this class of drug is now established as routine therapy in pati
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
3. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
4. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... Russia , July 10, 2014 ... Federation Dmitry Medvedev , presented Russia,s ... company BIOCAD . The Company is developing a ... of MabNext project BIOCAD develops a number of innovative ... and autoimmune diseases. The ceremony took place at the ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
(Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2
... constant currency revenue growth of 12.9 percent,- Full year ... and improving profitability reflects success of strategic ... for fiscal year 2009, BATESVILLE, Ind., Nov. 10 ... financial results for its fiscal,fourth quarter ended September 30, ...
... Incorporated,(Nasdaq: SPEX ) reported that the Nasdaq Stock ... its common stock from the Nasdaq,Global Market to the ... trading on the Nasdaq Capital Market on November 11, ... three market tier designations for,Nasdaq-listed stocks, and presently includes ...
... Conference Call Today at 4:30 p.m. Eastern Time -, ... MDVN ) today reported on its corporate progress and ... "The third quarter represented another quarter of significant,achievement and ... partnering,agreement with Pfizer for Dimebon. This collaboration not only ...
Cached Biology Technology:Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19Spherix Transfers Stock Listing to Nasdaq Capital Market 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... and services, previously announced on June 26, 2014 that ... dividend of $1.75 per share, or approximately $40 million ... July 10, 2014 and a payment date of July ... that it had set an ex-dividend date for this ...
(Date:7/10/2014)... -- It is a great honor for Avery Biomedical ... world-renowned Thoracic and Cardiovascular surgeon, Mark E Ginsburg, M.D., ... with over 34 years of experience, is currently practicing ... Regional Medical Center. Dr. Ginsburg has been implanting the ... considered an expert in the implantation of the Avery ...
(Date:7/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) ... Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, ... report to their offering ... Touch-Less Sensing Market to Grow Exponentially. Touch-less sensing ... the companies were unable to leverage this technology ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... body, particularly neuroproteins that maintain proper brain function. ... are known as "tangle diseases" because they are characterized ... brain. A team of Australian and American scientists ... be inserted into neuroproteins, causing them to misfold and ...
... world including science ministers from at least two nations ... September for a meeting that will explore new research and ... be held at the Sheraton Buenos Aires Hotel & Convention ... of science meetings from 1-4 October. Attendance is by invitation ...
... most extensively researched components in the diet. New studies ... of scientific research, which overall suggests that moderate habitual ... cardiovascular health Among recent studies, a new review ... consumption is unlikely to adversely affect cardiovascular health. Furthermore ...
Cached Biology News:New mechanism for protein misfolding may link to ALS 2TWAS to meet in dynamic Buenos Aires next week 2TWAS to meet in dynamic Buenos Aires next week 3
AedestaTM Animal Organ/Tissue Perfusion Soln....
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
... complementary RNA Spikes for the normalization and ... array printing and for protocol assessment and ... hybridization stringency and background. Normalize Cy3 and ... Oligo Spots, and complementary RNA Spikes for ...
Biology Products: